This is a preview of subscription content, log in via an institution to check access.
Notes
funded by Bayer Oy, Espoo, Finland
Reference
Soini E, et al. Cost-Effectiveness of Coronary and Peripheral Artery Disease Antithrombotic Treatments in Finland. Advances in Therapy : 9 Jun 2020. Available from: URL: http://dx.doi.org/10.1007/s12325-020-01398-8
Rights and permissions
About this article
Cite this article
Rivaroxaban plus aspirin cost effective as antithrombotic treatment in Finland. PharmacoEcon Outcomes News 856, 33 (2020). https://doi.org/10.1007/s40274-020-6933-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-6933-z